Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients

• Status: Completed
• Trial end date: 2017-05-22
• Target enrollment: 0
• Participant gender: All

Summary

This is a pilot, prospective randomized controlled study with the primary objective to evaluate and compare medical treatment of severe SHPT, namely oral cinacalcet versus surgical treatment, that is, parathyroidectomy with forearm autografting, on the progression of coronary artery and valvular calcification and left ventricular mass index in endstage renal disease patients receiving peritoneal dialysis over 12 months. The change in arterial stiffening, left ventricular volume, aortic valve calcium score and bone mineral density, nutritional status and biochemical parameters, quality of life measures will be evaluated as secondary objectives of this study.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The University of Hong Kong
• Treatments: Cinacalcet; Cinacalcet Hydrochloride

Criteria

Inclusion Criteria:

1. ESRD patients on long-term peritoneal dialysis treatment, with elevated intact parathyroid hormone (iPTH) levels > 800pg/mL.

2. Patients with parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan.

3. Patients with age between 18 - 75 years.

Exclusion Criteria:

1. Patients with background valvular heart disease

2. Patients who are unfit for general anaesthesia

3. Patients with acute myocardial infarction within recent two months

4. Patients with poor general condition

5. Patients with plans for living related kidney transplant within 1 year

6. Patients with previous history of parathyroidectomy

7. Patients with underlying malignancy

8. Patients with hepatic dysfunction